CA1245651A - Pyridazinones, preparation process thereof and utilization thereof, drugs containing pyridazinones - Google Patents

Pyridazinones, preparation process thereof and utilization thereof, drugs containing pyridazinones

Info

Publication number
CA1245651A
CA1245651A CA000481149A CA481149A CA1245651A CA 1245651 A CA1245651 A CA 1245651A CA 000481149 A CA000481149 A CA 000481149A CA 481149 A CA481149 A CA 481149A CA 1245651 A CA1245651 A CA 1245651A
Authority
CA
Canada
Prior art keywords
compound
denotes
general formula
acid
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000481149A
Other languages
English (en)
French (fr)
Inventor
Hermann Amschler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Application granted granted Critical
Publication of CA1245651A publication Critical patent/CA1245651A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA000481149A 1984-05-10 1985-05-09 Pyridazinones, preparation process thereof and utilization thereof, drugs containing pyridazinones Expired CA1245651A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2297/84-4 1984-05-10
CH229784 1984-05-10

Publications (1)

Publication Number Publication Date
CA1245651A true CA1245651A (en) 1988-11-29

Family

ID=4230485

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000481149A Expired CA1245651A (en) 1984-05-10 1985-05-09 Pyridazinones, preparation process thereof and utilization thereof, drugs containing pyridazinones

Country Status (15)

Country Link
US (1) US4665074A (enExample)
EP (1) EP0163965B1 (enExample)
JP (1) JPH062750B2 (enExample)
AT (1) ATE47844T1 (enExample)
AU (1) AU578947B2 (enExample)
CA (1) CA1245651A (enExample)
DE (1) DE3574137D1 (enExample)
DK (1) DK159431C (enExample)
ES (1) ES8607950A1 (enExample)
GR (1) GR851039B (enExample)
IE (1) IE58033B1 (enExample)
IL (1) IL75070A (enExample)
NZ (1) NZ211995A (enExample)
PT (1) PT80426B (enExample)
ZA (1) ZA853504B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59009351D1 (de) * 1989-04-17 1995-08-03 Byk Gulden Lomberg Chem Fab Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
EP0553174B1 (de) * 1990-10-16 1998-07-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Arylpyridazinone
WO1992019602A1 (de) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
EP0593567B1 (de) 1991-07-05 1996-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung substituierter pyridazine gegen dermatosen
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
ES2193539T3 (es) 1997-06-03 2003-11-01 Altana Pharma Ag Benzonaftiridinas.
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
EP1389468A4 (en) 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435244A1 (de) * 1974-07-22 1976-02-05 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
DE2445681A1 (de) * 1974-09-25 1976-04-15 Lentia Gmbh Verfahren zur herstellung von 3-phenylpyridazonen
JPS6037101B2 (ja) * 1977-03-09 1985-08-24 三共株式会社 フエニルピリダジノン誘導体の製法
DE2757923A1 (de) * 1977-12-24 1979-06-28 Hoechst Ag Verfahren zur herstellung von 3-pyridazonen
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
ES532337A0 (es) * 1983-05-11 1985-12-01 Byk Gulden Lomberg Chem Fab Procedimiento para la preparacion de 6-aril-3 (2h)piridazinonas
IT1173591B (it) * 1983-05-11 1987-06-24 Byk Gulden Lomberg Chem Fab Piridazioni,loro preparazione e impiego,farmaci contenenti piridazioni

Also Published As

Publication number Publication date
IL75070A0 (en) 1985-09-29
ZA853504B (en) 1985-12-24
GR851039B (enExample) 1985-05-28
IE851146L (en) 1985-11-10
EP0163965B1 (de) 1989-11-08
US4665074A (en) 1987-05-12
ATE47844T1 (de) 1989-11-15
DK177585D0 (da) 1985-04-19
NZ211995A (en) 1987-11-27
DK177585A (da) 1985-11-11
EP0163965A2 (de) 1985-12-11
EP0163965A3 (en) 1987-06-24
DK159431C (da) 1991-03-18
AU578947B2 (en) 1988-11-10
ES542979A0 (es) 1986-06-16
DE3574137D1 (en) 1989-12-14
DK159431B (da) 1990-10-15
PT80426A (de) 1985-06-01
JPS60246375A (ja) 1985-12-06
JPH062750B2 (ja) 1994-01-12
PT80426B (de) 1987-04-16
IL75070A (en) 1988-11-15
ES8607950A1 (es) 1986-06-16
IE58033B1 (en) 1993-06-16
AU4177585A (en) 1985-11-14

Similar Documents

Publication Publication Date Title
CA1245651A (en) Pyridazinones, preparation process thereof and utilization thereof, drugs containing pyridazinones
EP0482208B1 (en) Pyridazinone derivative
EP0469013B1 (de) Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
US4978665A (en) 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
WO1999024432A1 (fr) Derives de purine et medicament les renfermant en tant qu'ingredient actif
JP3080405B2 (ja) アミノスチルバゾール誘導体及び医薬
US4707481A (en) Pyridazinones, their preparation and use, and bronchospasmolytic medicaments containing pyridazinones
JP2002518377A (ja) アリールアルカノイルピリダジン
EP0376079A1 (en) 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A
JPWO1995027699A1 (ja) アミノスチルバゾール誘導体及び医薬
EP0201765B1 (en) 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
US4772598A (en) 2-aryl-3,4-diazabicyclo(4.n.O)alk-2-en-5-ones for the preparation of an agent for treating cardiac insufficiency
EP0089528A1 (de) 6-Aryl-4,5-dihydro-3(2H)-pyridazinone,ihre Herstellung und Verwendung
WO1984004522A1 (fr) Pyridazinone, son procede de preparation et son utilisation, medicaments contenant de la pyridazinone
JP2004528344A (ja) アルドースレダクターゼ阻害薬とシクロオキシゲナーゼ−２阻害薬の併用
AU2002236131A1 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
MXPA00008549A (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
MKEX Expiry